AI醫療科技新突破 台灣首創個人化「肺癌臨床智能決策輔助系統」

 (科技部)科技部長期深耕醫療科技研究，支持國內研究人員進行各項醫療技術發展，強化我國學術研究與產業發展的結合。本次成果在科技部補助下，由臺北醫學大學陳震宇特聘教授研究團隊，執行肺癌大數據精準醫療人工智慧系統計畫，以「早期預防、精確診斷、精準用藥」為目標，成功打造全台第一個醫病決策共享的「肺癌臨床智能決策輔助系統」(Clinical Decision Support System-Shared Decision Making, CDSS-SDM)，傑出的研究成果甫榮獲最新一屆FUTEX未來科技獎與國家新創獎。

肺癌是國人癌症的頭號殺手，唯有早期診斷、精準治療才能戰勝肺癌。肺癌治療決策需要多方面考量，臨床上肺癌早期診斷需要精準影像，治療與藥物選擇則需參考致癌基因變異等多重因素。肺癌從影像診斷的第一天起，病人就和時間賽跑，關鍵的前10天至少有4次檢查結果必須與經驗豐富的醫師共同討論治療決策，使用大數據和人工智慧有助於早期決策，提高醫療效能、達到肺癌精準臨床治療願景。

在科技部支持下，計畫團隊以深度學習為基礎，發展「肺癌臨床智能決策輔助系統」，根據臨床實際病程發生的流程，提供醫師與病患診斷、用藥、預後評估。團隊開發的「全自動低劑量電腦斷層肺癌基因突變預測模型」可自動從300多張電腦斷層影像自動偵測腫瘤，並精確切割運算，判斷腫塊類型和可能的基因突變，自動報告肺結節的處理建議。團隊更將電腦斷層預測結果和臨床大數據結合，透過肺腺癌病患醫療大數據和自動機器學習方法建立腦轉移、預後與藥物反應預測模組，當電腦斷層影像發現新發個案時，可立即預測腦轉移風險和選藥建議。

臺北醫學大學與臺灣醫療科技大廠雲象科技合作，開發可在全玻片數位病理浩瀚的細胞影像結構中，高速搜尋癌細胞並進行判讀之技術，並以此延伸開發全新的「全自動數位肺腺癌病理基因突變預測選藥模型」，可快速自動標註，並預測表皮生長因子受體(EGFR)最常見基因的突變狀態，結合病理與千人臨床數據，有助於提早精準用藥，相關成果，目前正積極申請海內外專利。

此外，團隊更以突破性技術開發「病理報告自然語言處理(NLP)自動判讀選藥建議系統」與「肺腺癌全基因用藥建議模型」，以人工智慧自然語言處理技術，輸入病人的一份病理報告即可自動得到存活率較高的健保與自費用藥推薦。並將治療效果和存活期做串聯，篩選出與病患相似且預後最佳的選藥治療建議，如同集合幾十個閱讀過上百份病理報告的專家共同所做的決策，有助於醫師和病人之間的決策分享，並依最新發展更新，讓醫病共享發揮到極致。對於晚期肺癌無法開刀或已經轉移復發，系統自動將病人狀況媒和全球新藥試驗場域，讓病人有機會媒合最適合的臨床試驗，為患者帶來新興的治療方向。

「肺癌臨床智能決策輔助系統」由臺北醫學大學與科技部攜手，集合跨領域生醫專家，將AI大數據加值，運用創新人工智慧肺癌模組，輔助臨床電腦斷層攝影與數位病理影像判讀，結合臨床數據與基因資料，成功開發出創新平台，將臺灣研究成果推向國際。讓肺癌早期診斷，個人化精準治療的醫病共享決策模式變成可能，進而創造科技突破造福人群，為患者帶來治癒的新希望。

波士頓市府發3萬9千元資助6移民組織擴辦精神健康服務

 

吳弭市長和移民發展服務辦處頒發精神健康服務小額贈款給六個移民服務組織

撥款 $39,000 給非營利組織，支持移民社區的精神健康服務

  波士頓市 — 市長吳弭(Michelle Wu) 和市長移民發展服務辦處（MOIA頒發 $39,000 小額贈款給六個移民服務組織。這些資金將幫助這些組織擴大移民社區的精神健康服務。

 吳市長說：「由於語言和文化障礙，傳統的精神健康服務用於移民社區可能具有挑戰性。這些非營利組織正在提供精神健康支援，以滿足當地居民的需求，我非常感激本市能夠對他們提供支援這些重要和及時的服務。」

 市長移民發展服務辦處主任 Yusufi Vali 說：「新冠病毒疫情對我們的移民社區產生更嚴重的影響。在我們從事疫情康復工作時，我們必須優先考慮精神健康，探索創新的康復方法。」

 這六個多元化移民服務非營利組織將個別獲得 $6,500 ，用於精神健康項目。這些項目包括不同的服務例如使用講故事的格式，、支持精神健康康復小組康和藝術展覽會。

 以下組織獲選接受 MOIA 精神健康小額贈款：

 亞裔美國人資源研討會（AARW）：每月在 Dorchester 與亞裔移民召開社區成員健康和精神健康支援會議

 巴西工人中心：透過開展為期八週的計劃，擴大他們的 Mulheres Vencedoras 專案，促進日常壓力管理和情感健康

 奇卡專案：利用培訓和談話解決導致拉丁裔和黑人女學生精神健康挑戰和自殺風險的社會和文化因素問題

 互助伊斯蒂社區治愈中心專案：舉辦藝術展覽會和開設培訓課程，注重在東波士頓開展和平團體等治愈活動

麻薩諸塞州家庭營養中心：每月舉辦兩次營養團體活動，並每週為 Dorchester、Allston、Brighton、Hyde Park 和 Roslindale 的佛得角移民提供獲得負擔得起的健康食品的機會

索馬里家長教育維權中心（SPACE）：在 Roslindale 和 Roxbury 為有殘障子女的索馬里移民家庭舉辦 10 次團體會議

 任何有意參加這些計劃的人都可以直接與上述個別非營利組織聯繫。

 MOIA 將與 Leah Zallman 移民健康研究中心合作，瞭解獲獎非營利組織如何改善移民的精神健康資源。研究結果可幫助指導本市的未來投資。

 關於波士頓市長移民發展服務辦處（Mayor’s Office for Immigrant Advancement）

波士頓市長移民發展服務辦處（MOIA）致力促進移民充分地、公平地參與波士頓經濟、市政、社會與文化生活。MOIA還努力推進對移民為本市所做貢獻的認可與公眾理解。若需瞭解更多資訊，請瀏覽boston.gov/immigrants。

MAYOR WU AND IMMIGRANT ADVANCEMENT AWARD

MENTAL HEALTH MINI-GRANTS

TO SIX IMMIGRANT-SERVING ORGANIZATIONS

$39,000 goes to nonprofits to support mental health programming for immigrant communities

BOSTON - TUESDAY, MAY 3, 2022 - Mayor Michelle Wu and the Mayor’s Office for Immigrant Advancement (MOIA) are awarding $39,000 in mini-grants to 6 immigrant-serving organizations. The funds will help organizations expand mental health programming for immigrant communities. 

“Accessing traditional mental health services can be challenging for immigrant communities because of barriers from language and culture,” said Mayor Wu. “These nonprofits are providing mental health support in a way that meets residents where they are, and I am grateful that the City can support their important and timely efforts.

“COVID-19 has disproportionately impacted our immigrant communities,” said Yusufi Vali, Director of the Mayor’s Office for Immigrant Advancement. “As we address recovery efforts, we must prioritize mental health and explore innovative ways to help people heal.”

The six diverse, immigrant-serving nonprofit organizations will each receive $6,500 for mental health programming. The programs include different services like storytelling, healing circles, and arts fairs. 

The following organizations are selected for the MOIA Mental Health Mini-Grants:

Asian American Resource Workshop (AARW): Hold monthly community wellness and mental health support sessions with Asian immigrants in Dorcheste

Brazilian Worker Center: Expand their Mulheres Vencedoras initiative with an 8-week program that promotes daily stress management and emotional wellness

Chica Project: Use training and conversations to address social and cultural factors that contribute to mental health challenges and suicide risks in Latinx and Black female students

Community Healing Center Project with Mutual Aid Eastie: Host art fairs and training sessions focused on healing practices like peace circles in East Boston

Family Nurturing Center for Massachusetts: Hold two monthly Nurturing Circles and provide weekly opportunities to access affordable healthy foods for Cape Verdean immigrants in Dorchester, Allston, Brighton, Hyde Park, and Roslindale

Somali Parents Advocacy Center for Education (SPACE): Provide 10 small group sessions in Roslindale and Roxbury for Somali immigrant families with children with disabilities

Anyone interested in joining these programs can reach out to the organization directly. 

MOIA will partner with the Leah Zallman Center for Immigrant Health Research to learn how the awardees improve mental health resources for immigrants. The results could help guide the City’s future investments.  

世界醫藥創新論壇 5/2-4日在波士頓舉行 今年主題基因和細胞療法(圖片)

 

DAY ONE RECAP | May 2, 2022 The 2022 World Medical Innovation Forum returned as an in-person event with a partnership between Mass General Brigham and Bank of America. Now in its eighth year, the Forum provides an unprecedented three-day immersion into the world of gene and cell therapies (GCT) and the investment opportunities emerging from this astonishing field. First Look Sessions Day 1 began with two sets of First Look sessions—rapid-fire presentations showcasing the next wave of GCT breakthroughs from 16 investigators across the Mass General Brigham system. Topics included host-microbiome interactions in health and disease; using reprogrammed stem cells to test strategies for the targeted degradation of tau as a treatment for Alzheimer’s disease; alternatives to immunosuppressive drugs to prevent rejection of transplanted organs and a 3D organoid platform to model the blood-brain barrier, among others. All of the First Look abstracts can be found here. The Doctor is In A new feature for the WMIF in 2022, a series of lunchtime “The Doctor is In” sessions provided attendees with an opportunity to take deeper dives into the scientific challenges and opportunities in GCT. Florian Eichler, MD, Director of the Center for Rare Neurological Diseases at Massachusetts General Hospital, discussed research and therapeutic efforts into single-gene correction in the brain. In a question and answer session with Tazeen Ahmad, Managing Director, Global Research, BofA Securities, Eichler was asked what criteria should be used to determine the safety of treatments and the tolerability of side effects, particularly when it comes to diseases that are often fatal when untreated. “Safety is always first and foremost on our mind as treating physicians who are engaging with patients” Eichler said. “As we work in this space, we’re constantly counseling families to weigh the risk-benefit of treatment to understand what to expect.” Lee Greenwood, whose child is being treated by Eichler for Canavan disease, expressed his heartfelt appreciation for Eichler’s efforts to identify and test new treatments and his openness about the risks involved. “My family, we certainly know the pros and cons,” Greenwood said. “We’re going into this with our eyes wide open. But we know what the path is when there is no hope, there is no treatment, and that path is awful. To have something, anything, where we can give our child some hope—it was an easy choice, honestly.” Opening Remarks The afternoon session began with a conversation with Anne Klibanski, MD, President and CEO of Mass General Brigham, and Brian Moynihan, Chair and CEO of Bank of America that was moderated by CNBC reporter Bertha Coombs. The discussion highlighted the need to improve data sharing within and across health care systems; the importance of preventive care and wellness initiatives to lower healthcare costs; and the need to work collectively to accelerate the development of new GCT treatments—and make them available to all patients. “It is bringing together the clinicians, the researchers, and the patients and being able to look at it from that perspective,” said Klibanski. “What are the right targets? What are the right first-in-human studies? How do we navigate this together in partnerships with industry, with venture, with government, with others, to really move this forward?” Co-Chair Panel In a panel discussion of WMIF co-chairs, several themes emerged—the excitement surrounding new therapies for previously untreatable diseases, the importance of collaborating across disciplines to move new treatments forward in the most cost-effective ways, and the need to engage patients as partners in the research process. “What’s so exciting about GCT is it is potentially curative,” said Marcela Maus, MD, PhD, Director of the Cellular Immunotherapy Program at the Mass General Cancer Center. “There are so many things in medicine where it is palliative, or where we treat symptomatically, or try to modify the outcome of disease without really getting at the fundamental mechanisms of the disease. You can get at that with gene and cell therapy.” The sentiment was echoed by Ravi Thadhani, MD, Chief Academic Officer of Mass General Brigham. “That’s what exciting about these next few days,” Thadhani said. “The opportunity to make a difference in those diseases that otherwise have been neglected or we had no therapies to deliver.” It was also clear from the discussion that more work needs to be done to accelerate the development process, identify new funding models and lower the cost of treatments. “We still have to answer questions on regulatory; we still have to answer questions on manufacturing,” said Geoff Meacham, PhD, Managing Director for Global Research for Bank of America Securities. “We can take something from the bench—can we go to the bedside? And beyond that, how do we get these things approved?” “We can’t do it alone. We need partnership,” said Miceal Chamberlain, President of Massachusetts, Northeast Regional Executive, Bank of America. “Everyone has to be aligned in this ecosystem in order for this to work.”

憲法營2017年在市府升基督教旗訟案勝訴 波士頓市府將制定升旗政策

             (Boston Orange 編譯) 美國最高法院5月2日裁定，波士頓市政府在2017年時拒絕讓有個十字的基督教旗幟在波士頓市府廣場升旗台上升起，是違反了一名西洛士百利人的憲法第一修正案權利。

             在退休中法官Stephen Breyer撰寫的裁定中，美國最高法院的所有9名法官都同意，波士頓市政府不應該不讓Harold Shurtleff的旗幟在市政府廣場升旗台上升起。

             曾是哈佛大學法學院教授既波士頓聯邦法院法官的Stephen Breyer寫道，”我們的結論是，波士頓市並不會以升起或飛揚一個私人集團的旗幟，作為政府言論的一種形式”。那意味著，波士頓市因為Shurtleff及憲法營 (Camp Constitution)的宗教觀點，拒絕升他們的旗幟，是限制了他們的言論自由。

            Harold Shurtleff是憲法營的領導，他在法院文件中辯稱，1787年的9月17日，美國憲法在費城簽署通過，該日成為憲法日該集團2017年向波士頓市政府申請許可，要在市政府廣場升旗台上升起基督教旗，是為紀念這日子。

            Harold Shurtleff早前在美國地方法院及上訴法庭第一巡迴庭申訴時，都敗訴了。

            美國最高法院在5月2日這天卻堅實的站在了Harold Shurtleff這邊。和Stephen Breyer一起簽名的法官還有John Roberts 、Sonia Sotomayor、Elena Kagan、Brett Kavanaugh、Amy Coney Barrett、Justices Samuel Alito、Clarence Thomas等法官，Neil Gorsuch法官發表了他自己的意見，Thomas. Kavanaugh也另外發表了同意的意見。

             根據Stephen Breyer的裁決文，在2005道2017年間，波士頓市府批准了284個非常多樣化的企業及組織升起旗幟，Harold Shurtleff的升旗要求是波士頓市府拒絕同意的唯一一個。

                       Stephen Breyer說，"我們必須回答的第一個基本問題是，波士頓的升旗是否會成為政府言論，如果是的話，波士頓可以根據觀點來拒絕旗幟。第一修正案的” 言論自由” 條款並未限制政府拒絕表達一種觀點，政府要運作也必須有觀點。由於波士頓市政府過去以來沒有積極參與旗幟挑選或訊息設計，讓法官們相信，升旗表達的是私人觀點，而不是政府觀點。在這樣的前提下，波士頓市政府基於宗教觀點拒絕讓Harold Shurtleff及憲法營升旗，就違法了第一修正案權利中的自由言論條款。

             波士頓市長吳弭 (Michelle Wu)接任市長，也承接了這問題。她的辦公室表示，她們現在會為在波士頓廣場升旗制定政策。他們將仔細檢視法院的決定，以及其對市政府經辦類似活動權力的認可。在波士頓市府考慮下一步之際，將確保波士頓的活動因應這一決定。